Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis C

A compound of formula I, including pharmaceutically acceptable salts thereof:

• wherein
• n, m are independently 0 or 1;
• R1 is methyl;
• R2 is phenyl that is independently substituted with 0-2 halo or methoxy or is para substituted with W—Ar1;
• W is —O— or —NH—;
• Ar1 is phenyl or para-halophenyl;
• R3 is hydrogen, halo, or alkyl;
• R4, R5, R6 are independently selected from hydrogen, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, hydroxyalkyloxy, alkoxyalkyloxy, COOR11 and CON(R12)(R13);
• R11 is hydrogen, alkyl or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• R12, R13 are each independently hydrogen, alkyl or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• or
• R12 and R13 can form a ring by joining two atoms, one from each of R12 and R13;
• R14 is hydrogen, alkyl or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy;
• R7 is hydrogen, alkyl, halo, N(R21)(R22), or alkylsulfonyl;
• R21 and R22 are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkylsulfonyl, or alkylsulfonylalkyl;
• or N(R21)(R22) taken together is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, and hydroxy;
• X, Y are independently selected from CR31R32, CO, O, NR33, NCN, S, SO, and S(O)2;
• R31, R32 are each independently alkyl or cycloalkyl, further substituted with 0-3 substituents;
• or
• R31 and R32 can form a ring by joining two atoms, one from each of R31 and R32;
• R33 is hydrogen, alkyl, cycloalkyl, or S(O)2R11 with 0-3 substituents selected from halo, haloalkoxy, OR11, NR12R13, COOR11, CONR12R13, S(O)2R11, S(O)2NR12R13, and NR14CONR12R13;
• Z is an alkylene or alkenylene chain containing 0-12 groups selected from the group consisting of O, NR41, S, S(O), S(O)2, C(O), C(O)O, C(O)NR41, C(S)NR41, O—C(O)NR41, NR41C(O)NR42, and Ar2, provided that any O or S atom does not directly bond to another O or S atom, such that ring A is 11-24 membered;
• and further wherein the alkylene or alkenylene chain is substituted with 0-6 substituents selected from alkyl, cycloalkyl, halo, alkoxy, haloalkyl, OH, OR11, haloalkoxy, NH2, NR12R13, COOR11, CONR12R13, S(O)2R11, S(O)2NR12R13, NR14CONR12R13, and Ar3;
• R41, R42 is hydrogen, alkyl or cycloalkyl with 0-3 substituents selected from halo, haloalkoxy, OR11, NR12R13, COOR11, CONR12R13, S(O)2R11, S(O)2NR12R13, and NR14CONR12R13;
• Ar2 is phenyl, 5-membered heteroaryl or 6-membered heteroaryl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, OH, OR11, haloalkoxy, NH2, NR12R13, COOR11, CONR12R13, S(O)2R11, S(O)2NR12R13, and NR14CONR12R13;
• Ar3 is phenyl, 5-membered heteroaryl or 6-membered heteroaryl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, OH, OR11, haloalkoxy, NH2, NR12R13, COOR11CONR12R13, S(O)2R11, S(O)2NR12R13, and NR14CONR12R13.